Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular disease: Much more aggressive in patients with type 2 diabetes

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

It is estimated that 80% of individuals with type 2 diabetes die of coronary heart disease. Several factors have been found to contribute to the accelerated atherosclerosis present in diabetic patients. These include hyperglycemia-induced endothelial cell dysfunction, impaired fibrinolysis, increased platelet aggregation, and dysfunctional arterial remodeling. The evidence supports that a healthy lifestyle, statin drugs, angiotensin-converting enzyme inhibitors, and aspirin can modify these factors and slow the atherosclerosis process observed in type 2 diabetes. Because of the high prevalence of cardiovascular disease in people with type 2 diabetes, early cardiac testing is indicated. The optimal strategy for coronary revascularization in diabetic patients remains controversial and is discussed in detail in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195–1200.

    Article  PubMed  CAS  Google Scholar 

  2. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998, 21:296–309.

    Article  Google Scholar 

  3. Mokdad AH, Serdula MK, Dietz WH, et al.: The continuing epidemic of obesity in the United States. JAMA 2000, 284:1650–1651.

    Article  PubMed  CAS  Google Scholar 

  4. Mokdad AH, Ford ES, Bowman BA, et al.: Diabetes trends in the U.S.: 1990–1998 [comment]. Diabetes Care 2000, 23:1278–1283.

    Article  PubMed  CAS  Google Scholar 

  5. Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990, 120:672–676.

    Article  PubMed  CAS  Google Scholar 

  6. American Diabetes Association. Diabetes Care 1996, 19(suppl 1):S96-S102.

    Google Scholar 

  7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  8. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. The finmonica myocardial infarction register study group. Diabetes Care 1998, 21:69–75.

    Article  PubMed  CAS  Google Scholar 

  9. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996, 27:567–574.

    Article  PubMed  CAS  Google Scholar 

  10. McVeigh GE, Brennan GM, Johnston GD, et al.: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992, 35:771–776.

    PubMed  CAS  Google Scholar 

  11. Fuller JH, Keen H, Jarrett RJ, et al.: Haemostatic variables associated with diabetes and its complications. BMJ 1979, 2:964–966.

    PubMed  CAS  Google Scholar 

  12. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al.: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998, 97:2213–2221.

    PubMed  CAS  Google Scholar 

  13. Moreno PR, Murcia AM, Palacios IF, et al.: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180–2184.

    PubMed  CAS  Google Scholar 

  14. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL: Platelet dysfunction in type 2 diabetes. Diabetes Care 2001, 24:1476–1485.

    Article  PubMed  CAS  Google Scholar 

  15. Gryglewski RJ, Botting RM, Vane JR: Mediators produced by the endothelial cell. Hypertension 1988, 12:530–548.

    PubMed  CAS  Google Scholar 

  16. Nolan RD, Platt KH, Loose PG: The resistance to nitric oxide inhibition of platelet aggregation is due to decreased phosphorylation of rap1B in platelets of NIDDM compared with control subjects [abstract]. Diabetes 1994, 43(suppl 1):101A.

  17. Kornowski R, Mintz GS, Lansky AJ, et al.: Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol 1998, 81:1298–1304.

    Article  PubMed  CAS  Google Scholar 

  18. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease--putative association via common antecedents; further evidence from the whitehall study. Diabetologia 1988, 31:737–740.

    Article  PubMed  CAS  Google Scholar 

  19. Perry IJ, Wannamethee SG, Walker MK, et al.: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men [comment]. BMJ 1995, 310:560–564.

    PubMed  CAS  Google Scholar 

  20. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC: Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men [comment]. BMJ 1995, 310:555–559.

    PubMed  CAS  Google Scholar 

  21. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H: Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Replication and extension in a Japanese cohort of male employees. Am J Epidemiol 1997, 145:103–109.

    PubMed  CAS  Google Scholar 

  22. Rimm EB, Manson JE, Stampfer MJ, et al.: Cigarette smoking and the risk of diabetes in women. Am J Pub Health 1993, 83:211–214.

    Article  PubMed  CAS  Google Scholar 

  23. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM: Insulin resistance and cigarette smoking [comment]. [Erratum appears in Lancet 1992, 13:339: 1492]. Lancet 1992, 339:1128–1130.

    Article  PubMed  CAS  Google Scholar 

  24. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994, 17:961–969.

    Article  PubMed  CAS  Google Scholar 

  25. Attvall S, Fowelin J, Lager I, Von Schenck H, Smith U: Smoking induces insulin resistance—a potential link with the insulin resistance syndrome. J Intern Med 1993, 233:327–332.

    Article  PubMed  CAS  Google Scholar 

  26. Wannamethee S, Goya PH, Shaper A, et al.: Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001, 24:1590–1595.

    Article  PubMed  CAS  Google Scholar 

  27. US Department of Health and Human Services. Diet and exercise dramatically delay type 2 diabetes; diabetes medication metformin also effective. Accessible at: http://www.nih.gov/news/pr/aug2001/niddk-08.htm accessed Oct 1 2001

  28. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  29. Hu FB, Stampfer MJ, Solomon C, et al.: Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001, 134:96–105.

    PubMed  CAS  Google Scholar 

  30. Maiorana A, O’Driscoll G, Cheetham C, et al.: The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001, 38:860–866.

    Article  PubMed  CAS  Google Scholar 

  31. Williamson DF, Thompson TJ, Thun M, et al.: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 1999, 23:1499–1504.

    Article  Google Scholar 

  32. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434–444.

    Article  PubMed  CAS  Google Scholar 

  33. Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.

    PubMed  CAS  Google Scholar 

  34. Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614–620.

    Article  PubMed  CAS  Google Scholar 

  35. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation 1998, 98:2513–2519.

    PubMed  CAS  Google Scholar 

  36. Anonymous: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998, 339:1349–1357.

    Google Scholar 

  37. Ni W, Egashira K, Kataoka C, et al.: Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001, 89:415–421.

    PubMed  CAS  Google Scholar 

  38. Moroi M, Zhang L, Yasuda T, et al.: Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998, 101:1225–1232.

    Article  PubMed  CAS  Google Scholar 

  39. Ni W, Egashira K, Kataoka C, et al.: Antiinflammatory and antiarteriosclerotic actions of HMG CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001, 89:415–421.

    PubMed  CAS  Google Scholar 

  40. Takemoto M, Egashira K, Usui M, et al.: Important role of tissue angiotensin- converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997, 99:278–287.

    PubMed  CAS  Google Scholar 

  41. Tomita H, Egashira K, Kubo-Inoue M, et al.: Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998, 18:1456–1464.

    PubMed  CAS  Google Scholar 

  42. Anonymous: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

  43. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. [Erratum appears in 2000, 342:1376 and 2000, 342:748]. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  44. Anonymous: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. Heart Outcomes Prevention Evaluation study investigators. [Erratum appears 2000, 356:860]. Lancet 2000, 355:253–259.

  45. Anonymous: Collaborative overview of randomised trials of antiplatelet therapy—i: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. [Erratum appears in 1994, 308:1540]. BMJ 1994, 308:81–106.

  46. Naka M, Hiramatsu K, Aizawa T, et al.: Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J 1992, 123:46–53.

    Article  PubMed  CAS  Google Scholar 

  47. Chiariello M, Indolfi C, Cotecchia MR, et al.: Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J 1985, 110:529–534.

    Article  PubMed  CAS  Google Scholar 

  48. Callaham PR, Froelicher VF, Klein J, et al.: Exercise-induced silent ischemia: age, diabetes mellitus, previous myocardial infarction and prognosis. J Am Coll Cardiol 1989, 14:1175–1180.

    Article  PubMed  CAS  Google Scholar 

  49. Chipkin SR, Frid D, Alpert JS, et al.: Frequency of painless myocardial ischemia during exercise tolerance testing in patients with and without diabetes mellitus. Am J Cardiol 1987, 59:61–65.

    Article  PubMed  CAS  Google Scholar 

  50. Nesto RW, Phillips RT, Kett KG, et al.: Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988, 108:170–175.

    PubMed  CAS  Google Scholar 

  51. Deedwania PC, Carbajal EV: Exercise test predictors of ambulatory silent ischemia during daily life in stable angina pectoris. Am J Cardiol 1990, 66:1151–1156.

    Article  PubMed  CAS  Google Scholar 

  52. Henderson RA, Pocock SJ, Sharp SJ, et al.: Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina [comment]. Lancet 1998, 352:1419–1425.

    Article  PubMed  CAS  Google Scholar 

  53. King SB 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS: Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) [comment]. J Am Coll Cardiol 2000, 35:1116–1121.

    Article  PubMed  Google Scholar 

  54. Kurbaan AS, Bowker TJ, Ilsley CD, et al., on behlf of the CABRI Investigators (Coronary Angioplasty versus Bypass Revascularization Investigation): Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001, 87:947–950.

    Article  PubMed  CAS  Google Scholar 

  55. Anonymous: Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the bypass angioplasty revascularization investigation (BARI). Circulation 1997, 96:1761–1769.

    Google Scholar 

  56. Detre KM, Lombardero MS, Brooks MM, et al.: The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N Engl J Med 1996, 335:217–225.

    Article  Google Scholar 

  57. The BARI Investigators: Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000, 35:1122–1129.

    Article  Google Scholar 

  58. Niles NW, McGrath PD, Malenka D, et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 2001, 37:1008–1015.

    Article  PubMed  CAS  Google Scholar 

  59. Abizaid A, Costa MA, Centemero M, et al.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Circulation 2001, 104:533–538.

    PubMed  CAS  Google Scholar 

  60. Marso SP, Lincoff AM, Ellis SG, et al.: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the epistent (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy [comment]. Circulation 1999, 100:2477–2484.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284-7872, San Antonio, TX, USA

    Elaine Chiquette PharmD & Robert Chilton DO

Authors
  1. Elaine Chiquette PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Chilton DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiquette, E., Chilton, R. Cardiovascular disease: Much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep 4, 134–142 (2002). https://doi.org/10.1007/s11883-002-0037-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-002-0037-z

Keywords

Search

Navigation